ResultsIQ

ResultsIQ › Latest results › Sai Life Sciences Limited

Sai Life Sciences Limited Q3 FY26 results press release summary

NSE: SAILIFE · BSE: 544306

Results press release of 5 Feb 2026, summarised by AI from the filing.

Sai Life Sciences Q3FY26 revenue ₹556 cr (+27%), EBITDA ₹191 cr (+54%), PAT ₹100 cr (+86%); ₹405 cr capex invested against FY26 plan of ₹700 cr.

Key takeaways

  1. Q3FY26 revenue Revenue from Operations ₹556 cr (Q3FY25: ₹440 cr, +27%), driven by strong growth both in CRO and CDMO services.
  2. FY26 capex ₹405 cr invested as on date against a plan of ₹700 cr for FY26, in line with the guided FY26 capex plan.
  3. Margin expansion EBITDA margin expanded by 605 bps to 34%, supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives.
  4. Growth driver Revenue growth was driven by strong growth both in CRO and CDMO services, supported by sustained demand and healthy volume growth across key service lines.
  5. Risk Forward-looking statements involve known or unknown risks and uncertainties that could cause actual results to differ materially from expectations.

Original filing on BSE

Sai Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹554 cr (+12% year on year), EBITDA ₹148 cr (+22% year on year), PAT ₹73.3 cr (+22% year on year), EBITDA margin 26.7% (+231 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹602 cr (+4% year on year), EBITDA ₹177 cr (+12% year on year), PAT ₹104 cr (+18% year on year), EBITDA margin 29.3% (+225 bps). Score 53 of 100, In line with trend. EBITDA margin rose 225 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.5% in 30 days (Nifty 500: −3.8%).
  • Q3 FY26: Revenue ₹556 cr (+26% year on year), EBITDA ₹188 cr (+57% year on year), PAT ₹100 cr (+86% year on year), EBITDA margin 33.8% (+649 bps). Score 92 of 100, Above trend. EBITDA margin rose 649 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +21.7% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹527 cr, EBITDA ₹140 cr, PAT ₹83.0 cr, EBITDA margin 26.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.0% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹483 cr, EBITDA ₹113 cr, PAT ₹58.0 cr, EBITDA margin 23.4%. Not scored. No result for the same quarter last year. Share price after the results: +8.7% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹567 cr, EBITDA ₹153 cr, PAT ₹90.0 cr, EBITDA margin 27.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.1% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹429 cr, EBITDA ₹112 cr, PAT ₹51.0 cr, EBITDA margin 26.1%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.